Cell And Gene Therapies: Where Few Standard Rules Apply
Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.
You may also be interested in...
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
BioMarin CMO Geoff Nichol envisions "fancy footwork" in future payer negotiations for groundbreaking hemophilia therapy, during a discussion on value at the 2018 Biotech Showcase meeting, held in conjunction with the J.P. Morgan conference.
At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.